Home

Our technologies

Targeted therapy: PTX-100

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T cell lymphomas.

Cell therapy: CellPryme

CellPryme is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. CellPryme-M can be briefly added to standard manufacturing processes. CellPryme-A is used as an adjuvant alongside cellular immunotherapy.

Cell therapy: OmniCAR

The OmniCAR platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. OmniCAR is a modular, universal CAR platform based on technology licensed from UPenn and Oxford University. It allows unprecedented control and flexibility over current generation CAR-T approaches.

Recent investor briefing

09 April, 2024

Register for an upcoming briefing or watch a previous session.

ASX: PTX

Click here to view our investor centre

ABOUT US

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

OUR PIPELINE

We have a diversified pipeline of later stage and emerging assets developed with world-leading partners including Yale, UPenn, Oxford and Moffitt and Peter MacCallum Cancer Centre.

INVESTOR PORTAL

Here you will find ASX announcements and share price data, along with other key company information. You can also subscribe for email updates and online investor briefings to engage with management directly.

STAY UP TO DATE

Register your details to receive company updates from Prescient Therapeutics

Media

Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research

A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…

Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research

A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…

Prescient Therapeutics: PTX-100 Phase 2 coming soon

Prescient Therapeutics update report 2024 08 29

Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…

Prescient Therapeutics: Current Developments in Cancer Treatment

Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific focus on blood cancers that…

Stay up to date

Register your details to receive company updates from Prescient Therapeutics.